The European Investment Bank (EIB) has announced a significant €20 million venture-debt financing deal with German medtech innovator Protembis. This funding is set to propel the development of Protembis’ cutting-edge ProtEmbo Cerebral Embolic Protection system, designed to safeguard patients’ brains during catheter-based heart procedures.
Protembis, known for its trailblazing approach to medical technology, will utilize the new capital to complete clinical trials, further research and development, and support its marketing efforts. The ProtEmbo system, a next-generation device that filters out embolic debris from the aortic arch, aims to reduce the risk of stroke and cognitive decline associated with procedures like transcatheter aortic valve replacement (TAVR). The innovative device is inserted through the left wrist, providing a less invasive alternative to traditional methods.
EIB Vice-President Nicola Beer emphasized the importance of this collaboration, stating, “This agreement underscores our dedication to supporting technologies that enhance patient health across Europe. Protembis’ advancement in cerebral protection technology represents a promising leap towards mitigating serious side effects for heart surgery patients.”
Protembis Co-CEOs Karl von Mangoldt and Conrad Rasmus expressed their enthusiasm, noting, “We are thrilled to finalize this agreement with the EIB. This funding marks a pivotal step forward in our mission to protect patients from brain injury during heart treatments. We extend our gratitude to the EIB team, our investors, and our board for their steadfast support.”
The EIB’s backing aligns with the InvestEU programme’s goal of fostering innovation and research, aiming to channel over €372 billion into cutting-edge technologies by 2027. Protembis’ success with ProtEmbo could redefine patient safety in cardiovascular procedures, highlighting the company’s commitment to improving healthcare outcomes globally.
Editorial Opinion
Protembis is at the forefront of addressing a critical gap in cardiovascular care. The €20 million investment from the EIB not only validates the company’s innovative approach but also sets a new standard for how emerging technologies can safeguard patient health. With a growing need for advanced solutions to prevent complications from minimally invasive heart procedures, Protembis is well-positioned to make a significant impact on the medical device industry. Their focus on cerebral protection aligns with broader healthcare trends prioritizing patient safety and procedural efficacy. As Protembis continues to advance its technology and expand its market reach, it is poised to become a leader in enhancing patient outcomes in cardiac care. Protembis or EIB.
If you need further assistance or have any corrections, please reach out to editor@thetimesmag.com.
